76
Views
4
CrossRef citations to date
0
Altmetric
CASE REPORT

A case of non‐Hodgkin's lymphoma‐associated pemphigus foliaceus and use of rituximab for treatment

&
Pages 368-370 | Received 13 Feb 2008, Accepted 13 Feb 2008, Published online: 19 Mar 2010

References

  • Chorzelski T. P., von Weiss J. F., Lever W. F. Clinical significance of autoantibodies in pemphigus. Arch Dermatol 1966; 93: 570–6
  • Anhalt G. J., Kim S. C., Stanley J. R., Korman N. J., Jabs D. A., Kory M., et al. Paraneoplastic pemphigus. An autoimmune mucocutaneous disease associated with neoplasia. N Engl J Med 1990; 323: 1729–35
  • Vu T. N., Lee T. X., Ndoye A., Shultz L. D., Pittelkow M. R., Dahl M. V., et al. The pathophysiological significance of nondesmoglein targets of pemphigus autoimmunity. Development of antibodies against keratinocyte cholinergic receptors in patients with pemphigus vulgaris and pemphigus foliaceus. Arch Dermatol 1998; 134: 971–80
  • Cotell X., Robinson N., Chan L. Autoimmune blistering skin diseases. Am J Emerg Med 2000; 18: 288–99
  • Ruocco V., Ruocco E. Pemphigus and environmental factors. G Ital Dermatol Venereol 2003; 138: 299–309
  • Kawana S., Hashimoto T., Nishikawa T., Nishiyama S. Changes in clinical features, histologic findings, and antigen profiles with development of pemphigus foliaceus from pemphigus vulgaris. Arch Dermatol 1994; 130: 1534–8
  • Jarzabek‐Chorzelska M., Jablonska S., Kolacinska‐Strasz Z., Sulej I. Immunopathological diagnosis of pemphigus foliaceus. Dermatology 2002; 205: 413–15
  • Hernandez C., Amagai M., Chan L. S. Pemphigus foliaceus: Preferential binding of IgG1 and C3 at the upper epidermis. Br J Dermatol 1997; 136: 249–52
  • Schmidt E., Hunzelmann N., Zillikens D., Bröcker E. B., Goebeler M. Rituximab in refractory autoimmune bullous diseases. Clin Exp Dermatol 2006; 31: 503–8
  • McLaughlin P., Grillo‐Lopez A. J., Link B. K., Levy R., Czuczman M. S., Williams M. E., et al. Rituximab chimeric anti‐CD20 monoclonal antibody therapy for relapsed indolent lymphoma: Half of patients respond to a four‐dose treatment program. J Clin Oncol 1998; 16: 2825–33
  • Edwards J. C., Szczepanski L., Szechinski J., Filipowicz‐Sosnowska A., Emery P., Close D. R., et al. Efficacy of B cell‐targeted therapy with rituximab in patients with rheumatoid arthritis. N Engl J Med 2004; 350: 2572–81
  • Quartier P., Brethon B., Phillippet P., Landman‐Parker J., Le Deist F., Fischer A. Treatment of childhood autoimmune hemolytic anemia with rituximab. Lancet 2001; 358: 1511–13
  • Torzecka J. D., Sysa‐Jedrzejowska A., Dziankowska‐Bartkowiak B., Waszczykowska E. Pemphigus foliaceus: An unusual clinical feature and case reports. Cutis 1998; 61: 21–4
  • Arin M., Engert A., Krieg T., Hunzelmann N. Anti‐CD20 monoclonal antibody in the treatment of pemphigus. Br J Dermatol 2005; 51: 620–5

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.